Syngene International Limited (BOM:539268)
705.10
+2.75 (0.39%)
At close: Aug 4, 2025
Syngene International Employees
Syngene International had 6,533 employees as of March 31, 2025. The number of employees increased by 23 or 0.35% compared to the previous year.
Employees
6,533
Change (1Y)
23
Growth (1Y)
0.35%
Revenue / Employee
$5,705,189
Profits / Employee
$776,366
Market Cap
260.83B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 6,533 | 23 | 0.35% |
Mar 31, 2024 | 6,510 | -337 | -4.92% |
Mar 31, 2023 | 6,847 | 872 | 14.59% |
Mar 31, 2022 | 5,975 | 538 | 9.90% |
Mar 31, 2021 | 5,437 | 491 | 9.93% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
Reliance Industries | 347,362 |
HDFC Bank | 214,521 |
Bharti Airtel | 13,593 |
Tata Consultancy Services | 607,979 |
ICICI Bank | 182,665 |
State Bank of India | 236,226 |
Infosys | 323,578 |
Hindustan Unilever | 18,802 |
Syngene International News
- 15 days ago - Goldman Sachs maintains buy on Syngene, bullish on FY26 early-teens growth outlook, sees 15.5% upside on Q1 beat and rising CRO-led margin gains - Business Upturn
- 17 days ago - Syngene Q1 profit up 59% to Rs 87 crore - The Times of India
- 17 days ago - Syngene International Q1 Results: Revenue grows 11% YoY to Rs 790 crore, Net profit jumps 59% YoY - Business Upturn
- 2 months ago - Syngene International receives EIR from USFDA for Biocon Park facility, inspection concludes with VAI classification - Business Upturn
- 3 months ago - Why are Syngene shares down 10% despite Q4 net profit jumping 2.8% YoY? - Business Upturn
- 3 months ago - Syngene International shares hit lower circuit crashing to 10% today after Q4 results - Business Upturn
- 5 months ago - Syngene International shares down 2.50% after USFDA issues Form 483 with five observations - Business Upturn
- 6 months ago - Suven Pharmaceuticals shares surge 12% as Macquarie initiates ‘Outperform’ rating with target price of Rs 1,500, estimating 29.9% upside potential - Business Upturn